TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib
Authors:
Open Access
- 28 February 2020
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 126, 109862
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81803954)
- Fudan University
- Fundamental Research Funds for the Central Universities (2018-JYBZZ-XJSJJ003)
This publication has 43 references indexed in Scilit:
- Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivoBiochemical Pharmacology, 2012
- Molecular mechanisms of vascular effects of High‐density lipoprotein: alterations in cardiovascular diseaseEMBO Molecular Medicine, 2012
- Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cellsCancer Biology & Therapy, 2010
- Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cellsJournal of Biomedical Science, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft modelsCancer Chemotherapy and Pharmacology, 2006
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Tandem Mass Tags: A Novel Quantification Strategy for Comparative Analysis of Complex Protein Mixtures by MS/MSAnalytical Chemistry, 2003
- All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferasesGlycobiology, 2002
- Proteome and proteomics: New technologies, new concepts, and new wordsElectrophoresis, 1998